Lucira Health, Inc. (NASDAQ:LHDX – Get Rating) was the target of some unusual options trading activity on Monday. Traders purchased 3,345 call options on the stock. This represents an increase of 3,790% compared to the average daily volume of 86 call options.
Lucira Health Stock Performance
NASDAQ LHDX opened at $0.51 on Tuesday. The company has a 50-day simple moving average of $0.28 and a two-hundred day simple moving average of $0.83. The company has a quick ratio of 0.79, a current ratio of 1.46 and a debt-to-equity ratio of 0.48. Lucira Health has a 12-month low of $0.11 and a 12-month high of $5.67. The firm has a market cap of $20.45 million, a price-to-earnings ratio of -0.14 and a beta of 4.31.
Get Lucira Health alerts:Hedge Funds Weigh In On Lucira Health
Several hedge funds and other institutional investors have recently modified their holdings of the company. AlphaCentric Advisors LLC bought a new position in Lucira Health in the third quarter worth about $339,000. Vanguard Group Inc. grew its holdings in shares of Lucira Health by 23.4% during the first quarter. Vanguard Group Inc. now owns 631,767 shares of the company's stock valued at $2,256,000 after buying an additional 119,929 shares during the last quarter. EPIQ Capital Group LLC boosted its holdings in Lucira Health by 0.7% in the third quarter. EPIQ Capital Group LLC now owns 13,737,370 shares of the company's stock worth $14,562,000 after purchasing an additional 97,502 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Lucira Health in the second quarter worth approximately $78,000. Finally, Prudential Financial Inc. purchased a new stake in Lucira Health in the second quarter worth approximately $32,000. 57.02% of the stock is owned by institutional investors.
Lucira Health Company Profile
(Get Rating)
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.
Recommended Stories
- Get a free copy of the StockNews.com research report on Lucira Health (LHDX)
- Reserve Your Spot With These Hotels The Analysts Support
- Cruise Line Stocks Still Have Some Choppy Waters to Navigate
- Four Vegan Food Stocks Performing Beyond the Norm
- Ocean Interest Electrifies Fisker Stock
- Is Freshpet Ready For A Fresh Rally?
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.